Acquisition by Graf Finckenstein Friedrich of 2812 shares of Iovance Biotherapeutics subject to Rule 16b-3

IOVA Stock  USD 5.35  0.01  0.19%   
About 62% of Iovance Biotherapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Iovance Biotherapeutics suggests that many traders are alarmed. The current market sentiment, together with Iovance Biotherapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Iovance Biotherapeutics stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Iovance Biotherapeutics Officer Chief Medical Officer. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Iovance insider trading alert for acquisition of common stock by Graf Finckenstein Friedrich, Officer: Chief Medical Officer, on 12th of October 2024. This event was filed by Iovance Biotherapeutics with SEC on 2024-04-15. Statement of changes in beneficial ownership - SEC Form 4

Iovance Biotherapeutics Fundamental Analysis

We analyze Iovance Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iovance Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iovance Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Debt To Equity

Debt To Equity Comparative Analysis

Iovance Biotherapeutics is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Iovance Biotherapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Iovance Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Iovance Biotherapeutics could also be used in its relative valuation, which is a method of valuing Iovance Biotherapeutics by comparing valuation metrics with similar companies.

Complementary Tools for Iovance Stock analysis

When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Fundamental Analysis
View fundamental data based on most recent published financial statements
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital